Loading...
•
Sep 30, 2022
Vanda Q3 2022 Earnings Report
Reported financial results for the third quarter ended September 30, 2022.
Key Takeaways
Vanda Pharmaceuticals reported a total revenue of $65.3 million and a net income of $3.3 million for Q3 2022. The company is focusing on commercial execution and pipeline advancement.
Total revenues for Q3 2022 were $65.3 million.
HETLIOZ® net product sales were $41.3 million in Q3 2022, a 9% decrease compared to Q3 2021.
Fanapt® net product sales were $24.0 million in Q3 2022, a 2% decrease compared to Q3 2021.
Net income was $3.3 million in Q3 2022 compared to $7.8 million in Q3 2021.
Revenue by Segment
Forward Guidance
Vanda is updating its 2022 financial guidance and expects to achieve the following financial objectives in 2022:
Positive Outlook
- Total revenues are expected to be between $240 to $270 million.
- HETLIOZ® net product sales are expected to be between $150 to $170 million.
- Fanapt® net product sales are expected to be between $90 to $100 million.
- Year-end 2022 Cash is expected to be greater than $450 million.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...